Lahey Hospital and Medical Center, Burlington, MA.
Yale School of Medicine, New Haven, CT.
J Am Coll Surg. 2021 Jun;232(6):848-854. doi: 10.1016/j.jamcollsurg.2021.01.016. Epub 2021 Feb 23.
Postoperative hypocalcemia is the most common complication after thyroidectomy. Postoperative supplementation with calcium and calcitriol reduces its occurrence; however, prophylactic preoperative supplementation has not been studied systematically. The primary objective of this study was to determine whether pre- and postoperative calcium and calcitriol supplementation reduces postoperative hypocalcemia after total thyroidectomy compared with postoperative supplementation alone.
We conducted a single-institution prospective randomized trial enrolling 82 patients undergoing total thyroidectomy from July 2017 through May 2019. Those undergoing partial thyroidectomy or concurrent planned parathyroidectomy were excluded. The intervention group started calcitriol 0.25 μg po bid and calcium carbonate 1,500 mg po tid 5 days preoperatively and continued postoperatively. The control group started these medications postoperatively. The primary end point was clinical or biochemical hypocalcemia. Secondary outcomes were postoperative calcium levels, need for intervention, length of stay, and readmission.
Thirty-eight patients were randomized to the intervention group and 44 to the control group. There were 12 episodes of hypocalcemia; 5 (13.2%) in the intervention and 7 (15.9%) in the control group (p = 0.76). No differences were found in secondary outcomes; including postoperative calcium levels at each measured time point, need for intervention (n = 10 [26.3%], n = 15 [34.1%]; p = 0.48), length of stay (mean [SD] 32.3 [15.6] hours, 30.7 [10.5] hours; p = 0.6), or readmissions (n = 0 [0.0%], n = 3 [6.8%]; p = 0.24).
Starting supplementation with calcium and calcitriol preoperatively does not reduce postoperative hypocalcemia compared with postoperative supplementation alone after total thyroidectomy. These findings do not support the practice of routine calcium and calcitriol supplementation before total thyroidectomy.
甲状腺切除术后低钙血症是最常见的并发症。术后补充钙和骨化三醇可降低其发生率;然而,预防性术前补充尚未得到系统研究。本研究的主要目的是确定与仅术后补充相比,术前和术后补充钙和骨化三醇是否可降低全甲状腺切除术后的术后低钙血症。
我们进行了一项单中心前瞻性随机试验,纳入了 2017 年 7 月至 2019 年 5 月期间行全甲状腺切除术的 82 例患者。排除行部分甲状腺切除术或同期计划甲状旁腺切除术的患者。干预组在术前 5 天开始口服骨化三醇 0.25μg,bid 和碳酸钙 1500mg,tid,并继续术后服用。对照组在术后开始服用这些药物。主要终点是临床或生化低钙血症。次要结局是术后血钙水平、需要干预、住院时间和再入院。
38 例患者被随机分配到干预组,44 例患者被分配到对照组。发生低钙血症 12 例;干预组 5 例(13.2%),对照组 7 例(15.9%)(p=0.76)。在次要结局方面也没有差异;包括每个测量时间点的术后血钙水平、需要干预的情况(n=10 [26.3%],n=15 [34.1%];p=0.48)、住院时间(平均[标准差]32.3[15.6]小时,30.7[10.5]小时;p=0.6)或再入院(n=0 [0.0%],n=3 [6.8%];p=0.24)。
与全甲状腺切除术后仅术后补充相比,术前开始补充钙和骨化三醇并不能降低术后低钙血症。这些发现不支持全甲状腺切除术前常规补充钙和骨化三醇的做法。